全球领先的制药公司诺华和礼来近日宣布，与Alphabet（谷歌母公司）旗下的AI制药企业Isomorphic Labs达成一项新的战略合作。据双方透露，这项合作的价值高达30亿美元。
Isomorphic Labs是一家专注于利用人工智能技术开发新药的创新型企业。此次与诺华和礼来的合作，将主要集中在小分子药物的研发上，涉及多个靶点。据悉，这些合作可能会为Isomorphic Labs带来近30亿美元的商业价值，但这部分价值并不包括未来药物销售可能产生的特许权使用费。
这次合作是Isomorphic Labs在医药领域的又一重要布局。作为一家AI制药企业，Isomorphic Labs一直致力于利用人工智能技术提高药物研发的效率和成功率。此次与诺华和礼来的合作，不仅有助于推动小分子药物的研发进程，也将进一步提升Isomorphic Labs在全球制药行业的竞争力。
对于诺华和礼来来说，这次合作也是一个重要的战略选择。通过与Isomorphic Labs的合作，两家公司可以借助AI技术加速新药的研发，提高研发效率，降低研发成本，从而更好地满足患者的需求。
总的来说，这次诺华、礼来与Isomorphic Labs的合作，无疑是一次三赢的合作。它将推动AI技术在医药领域的应用，加速新药的研发进程，同时也将为全球患者带来更多优质的治疗方案。
英语如下：
Headline: “AI Drug Maker Isomorphic Labs Forms $3 Billion Collaboration with Eli Lilly and Novartis to Target Small Molecule Drug Development”
Keywords: AI drug making, strategic collaboration, $3 billion
The global leaders in pharmaceuticals, Novartis and Eli Lilly, have announced a new strategic partnership with Isomorphic Labs, an AI drug maker owned by Alphabet (Google’s parent company). The partnership is valued at $3 billion, according to both parties.
Isomorphic Labs is an innovative enterprise specializing in the development of new drugs using artificial intelligence technology. This collaboration with Novartis and Eli Lilly will focus on small molecule drug development, covering multiple targets. It is reported that these collaborations may bring Isomorphic Labs nearly $3 billion in commercial value, but this does not include royalties from future drug sales.
This collaboration is another important move for Isomorphic Labs in the field of medicine. As an AI drug maker, Isomorphic Labs has been committed to using AI technology to improve the efficiency and success rate of drug research. This collaboration with Novartis and Eli Lilly will not only help to promote the development of small molecule drugs but will also further enhance Isomorphic Labs’ competitiveness in the global pharmaceutical industry.
For Novartis and Eli Lilly, this collaboration is also an important strategic choice. By partnering with Isomorphic Labs, the two companies can accelerate the development of new drugs using AI technology, improve R&D efficiency, and reduce R&D costs, thereby better meeting the needs of patients.
In summary, this collaboration between Novartis, Eli Lilly, and Isomorphic Labs is undoubtedly a win-win situation. It will promote the application of AI technology in the field of medicine, accelerate the development of new drugs, and provide more quality treatment plans for patients worldwide.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 4